West Pharmaceutical Services (WST) Equity Average (2010 - 2026)

West Pharmaceutical Services' Equity Average history runs 17 years deep, the most recent figure standing at $3.1 billion for Q1 2026.

• In Q1 2026, Equity Average rose 14.93% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $3.1 billion (up 14.93% YoY), while the FY2025 annual figure was $2.9 billion, up 5.3% from the prior year.
• Equity Average came in at $3.1 billion for Q1 2026 at West Pharmaceutical Services, down from $3.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $3.1 billion in Q4 2025 to a low of $2.3 billion in Q1 2022.
• A 5-year average of $2.7 billion and a median of $2.7 billion in 2023 frame the typical range for Equity Average.
• Across the five-year window, Equity Average gained 26.55% in 2022 and fell 5.48% in 2024, its largest moves.
• West Pharmaceutical Services' Equity Average stood at $2.6 billion in 2022, then climbed by 11.51% to $2.9 billion in 2023, then decreased by 5.48% to $2.7 billion in 2024, then gained by 14.59% to $3.1 billion in 2025, then decreased by 0.98% to $3.1 billion in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $3.1 billion, $3.1 billion, and $3.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison